JP2004536814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536814A5 JP2004536814A5 JP2003501988A JP2003501988A JP2004536814A5 JP 2004536814 A5 JP2004536814 A5 JP 2004536814A5 JP 2003501988 A JP2003501988 A JP 2003501988A JP 2003501988 A JP2003501988 A JP 2003501988A JP 2004536814 A5 JP2004536814 A5 JP 2004536814A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- phenyl
- alkyl
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 21
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- -1 p -pyridyl Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000012038 nucleophile Substances 0.000 claims 2
- XQJJVSKZRKYETA-UHFFFAOYSA-N 2-(2-hydroxyethylamino)-4-(4-phenylpiperidin-1-yl)-6-(2,2,2-trifluoroethoxy)pyrimidine-5-carbonitrile Chemical compound OCCNC1=NC(OCC(F)(F)F)=C(C#N)C(N2CCC(CC2)C=2C=CC=CC=2)=N1 XQJJVSKZRKYETA-UHFFFAOYSA-N 0.000 claims 1
- SZDRMFIBAQVXRC-UHFFFAOYSA-N 2-(cyclopropylamino)-4-(2-hydroxyethylamino)-6-(4-phenylpiperazin-1-yl)pyrimidine-5-carbonitrile Chemical compound N=1C(N2CCN(CC2)C=2C=CC=CC=2)=C(C#N)C(NCCO)=NC=1NC1CC1 SZDRMFIBAQVXRC-UHFFFAOYSA-N 0.000 claims 1
- ATHYGWDFZLNGSU-UHFFFAOYSA-N 2-(cyclopropylamino)-4-(2-hydroxyethylamino)-6-(4-phenylpiperidin-1-yl)pyrimidine-5-carbonitrile Chemical compound N=1C(N2CCC(CC2)C=2C=CC=CC=2)=C(C#N)C(NCCO)=NC=1NC1CC1 ATHYGWDFZLNGSU-UHFFFAOYSA-N 0.000 claims 1
- XPCJOWNVLUTJEY-UHFFFAOYSA-N 2-(cyclopropylamino)-4-[4-(4-fluorophenyl)piperazin-1-yl]-6-(2-hydroxyethylamino)pyrimidine-5-carbonitrile Chemical compound N=1C(N2CCN(CC2)C=2C=CC(F)=CC=2)=C(C#N)C(NCCO)=NC=1NC1CC1 XPCJOWNVLUTJEY-UHFFFAOYSA-N 0.000 claims 1
- GUIBPEGBMRNZEX-UHFFFAOYSA-N 2-(cyclopropylmethylamino)-4-(2-hydroxyethylamino)-6-(4-phenylpiperazin-1-yl)pyrimidine-5-carbonitrile Chemical compound N=1C(N2CCN(CC2)C=2C=CC=CC=2)=C(C#N)C(NCCO)=NC=1NCC1CC1 GUIBPEGBMRNZEX-UHFFFAOYSA-N 0.000 claims 1
- ZZTVMDZWZADEJR-UHFFFAOYSA-N 2-(cyclopropylmethylamino)-4-(2-hydroxyethylamino)-6-(4-phenylpiperidin-1-yl)pyrimidine-5-carbonitrile Chemical compound N=1C(N2CCC(CC2)C=2C=CC=CC=2)=C(C#N)C(NCCO)=NC=1NCC1CC1 ZZTVMDZWZADEJR-UHFFFAOYSA-N 0.000 claims 1
- MLLHCQYZLJRAMG-UHFFFAOYSA-N 2-(cyclopropylmethylamino)-4-[4-(4-fluorophenyl)piperazin-1-yl]-6-(2-hydroxyethylamino)pyrimidine-5-carbonitrile Chemical compound N=1C(N2CCN(CC2)C=2C=CC(F)=CC=2)=C(C#N)C(NCCO)=NC=1NCC1CC1 MLLHCQYZLJRAMG-UHFFFAOYSA-N 0.000 claims 1
- UFNWEBRZVIBAKV-UHFFFAOYSA-N 2-(cyclopropylmethylamino)-4-[4-(4-fluorophenyl)piperidin-1-yl]-6-(2-hydroxyethylamino)pyrimidine-5-carbonitrile Chemical compound N=1C(N2CCC(CC2)C=2C=CC(F)=CC=2)=C(C#N)C(NCCO)=NC=1NCC1CC1 UFNWEBRZVIBAKV-UHFFFAOYSA-N 0.000 claims 1
- YSRVJHFURSGIDG-UHFFFAOYSA-N 2-[6-[4-(4-fluorophenyl)piperazin-1-yl]-2-methyl-5-nitropyrimidin-4-yl]oxyethanol Chemical compound CC1=NC(OCCO)=C([N+]([O-])=O)C(N2CCN(CC2)C=2C=CC(F)=CC=2)=N1 YSRVJHFURSGIDG-UHFFFAOYSA-N 0.000 claims 1
- BYWNGKMBKPMAMZ-UHFFFAOYSA-N 2-methyl-5-nitro-6-(4-phenylpiperidin-1-yl)-3-(2,2,2-trifluoroethyl)pyrimidin-4-one Chemical compound O=C1N(CC(F)(F)F)C(C)=NC(N2CCC(CC2)C=2C=CC=CC=2)=C1[N+]([O-])=O BYWNGKMBKPMAMZ-UHFFFAOYSA-N 0.000 claims 1
- WETWIACDXYEMAE-UHFFFAOYSA-N 3-(2-hydroxyethylamino)-5-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)-1,2,4-triazine-6-carbonitrile Chemical group OCCNC1=NN=C(C#N)C(N2CC=C(CC2)C=2C=CC=CC=2)=N1 WETWIACDXYEMAE-UHFFFAOYSA-N 0.000 claims 1
- CAVHNPFNSQJIBO-UHFFFAOYSA-N 3-[4-(4-fluorophenyl)piperazin-1-yl]-5-methyl-6-phenylpyrazine-2-carbonitrile Chemical compound N#CC=1N=C(C=2C=CC=CC=2)C(C)=NC=1N(CC1)CCN1C1=CC=C(F)C=C1 CAVHNPFNSQJIBO-UHFFFAOYSA-N 0.000 claims 1
- MUJXTUPZYNZRIG-UHFFFAOYSA-N 4-(2-hydroxyethylamino)-6-(4-phenylpiperidin-1-yl)-2-(pyridin-3-ylmethylamino)pyrimidine-5-carbonitrile Chemical compound N=1C(N2CCC(CC2)C=2C=CC=CC=2)=C(C#N)C(NCCO)=NC=1NCC1=CC=CN=C1 MUJXTUPZYNZRIG-UHFFFAOYSA-N 0.000 claims 1
- KAYMQNZOONGXTI-UHFFFAOYSA-N 4-(4-phenylpiperidin-1-yl)-2-(pyridin-3-ylmethylamino)-6-(2,2,2-trifluoroethoxy)pyrimidine-5-carbonitrile Chemical compound N=1C(N2CCC(CC2)C=2C=CC=CC=2)=C(C#N)C(OCC(F)(F)F)=NC=1NCC1=CC=CN=C1 KAYMQNZOONGXTI-UHFFFAOYSA-N 0.000 claims 1
- DBVWLINRVSEHBF-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)piperidin-1-yl]-2-(2-hydroxyethylamino)-6-(2,2,2-trifluoroethoxy)pyrimidine-5-carbonitrile Chemical compound OCCNC1=NC(OCC(F)(F)F)=C(C#N)C(N2CCC(CC2)C=2C=CC(F)=CC=2)=N1 DBVWLINRVSEHBF-UHFFFAOYSA-N 0.000 claims 1
- JZYSFRCVPMRUKL-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)piperidin-1-yl]-2-(pyridin-3-ylmethylamino)-6-(2,2,2-trifluoroethoxy)pyrimidine-5-carbonitrile Chemical compound C1=CC(F)=CC=C1C1CCN(C=2C(=C(OCC(F)(F)F)N=C(NCC=3C=NC=CC=3)N=2)C#N)CC1 JZYSFRCVPMRUKL-UHFFFAOYSA-N 0.000 claims 1
- SWWDHOHMVFMUDK-UHFFFAOYSA-N 4-chloro-2-(2-hydroxyethylamino)-6-(4-phenylpiperidin-1-yl)pyrimidine-5-carbonitrile Chemical compound OCCNC1=NC(Cl)=C(C#N)C(N2CCC(CC2)C=2C=CC=CC=2)=N1 SWWDHOHMVFMUDK-UHFFFAOYSA-N 0.000 claims 1
- DUTMZYIWHLQZTH-UHFFFAOYSA-N 5-ethyl-6-methyl-3-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)pyrazine-2-carbonitrile Chemical compound N1=C(C)C(CC)=NC(N2CC=C(CC2)C=2C=CC=CC=2)=C1C#N DUTMZYIWHLQZTH-UHFFFAOYSA-N 0.000 claims 1
- RYGSYSQTYIDSSG-UHFFFAOYSA-N 5-ethyl-6-methyl-3-(4-phenylpiperidin-1-yl)pyrazine-2-carbonitrile Chemical compound N1=C(C)C(CC)=NC(N2CCC(CC2)C=2C=CC=CC=2)=C1C#N RYGSYSQTYIDSSG-UHFFFAOYSA-N 0.000 claims 1
- DWDNQKHCVOKXBO-UHFFFAOYSA-N 6-[4-(4-fluorophenyl)piperazin-1-yl]-2-methyl-5-nitro-3-(2,2,2-trifluoroethyl)pyrimidin-4-one Chemical compound O=C1N(CC(F)(F)F)C(C)=NC(N2CCN(CC2)C=2C=CC(F)=CC=2)=C1[N+]([O-])=O DWDNQKHCVOKXBO-UHFFFAOYSA-N 0.000 claims 1
- WWMAVCQJXALCEP-UHFFFAOYSA-N 6-[4-(4-fluorophenyl)piperazin-1-yl]-3-(2-hydroxyethyl)-2-methyl-5-nitropyrimidin-4-one Chemical compound O=C1N(CCO)C(C)=NC(N2CCN(CC2)C=2C=CC(F)=CC=2)=C1[N+]([O-])=O WWMAVCQJXALCEP-UHFFFAOYSA-N 0.000 claims 1
- PAIAITMMROUGMU-UHFFFAOYSA-N 6-[4-(4-fluorophenyl)piperidin-1-yl]-2-methyl-5-nitro-3-(2,2,2-trifluoroethyl)pyrimidin-4-one Chemical compound O=C1N(CC(F)(F)F)C(C)=NC(N2CCC(CC2)C=2C=CC(F)=CC=2)=C1[N+]([O-])=O PAIAITMMROUGMU-UHFFFAOYSA-N 0.000 claims 1
- DJPFNIBTNYHCHV-UHFFFAOYSA-N 6-[4-(4-fluorophenyl)piperidin-1-yl]-3-(2-methoxyethyl)-2-methyl-5-nitropyrimidin-4-one Chemical compound O=C1N(CCOC)C(C)=NC(N2CCC(CC2)C=2C=CC(F)=CC=2)=C1[N+]([O-])=O DJPFNIBTNYHCHV-UHFFFAOYSA-N 0.000 claims 1
- NUUCWXKVRPMGDL-UHFFFAOYSA-N 6-ethyl-5-methyl-3-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)pyrazine-2-carbonitrile Chemical compound N1=C(C)C(CC)=NC(C#N)=C1N1CC=C(C=2C=CC=CC=2)CC1 NUUCWXKVRPMGDL-UHFFFAOYSA-N 0.000 claims 1
- XGWHHFSNYXBNAY-UHFFFAOYSA-N 6-ethyl-5-methyl-3-(4-phenylpiperazin-1-yl)pyrazine-2-carbonitrile Chemical compound N1=C(C)C(CC)=NC(C#N)=C1N1CCN(C=2C=CC=CC=2)CC1 XGWHHFSNYXBNAY-UHFFFAOYSA-N 0.000 claims 1
- ARTMWBNETUDYDF-UHFFFAOYSA-N 6-ethyl-5-methyl-3-(4-phenylpiperidin-1-yl)pyrazine-2-carbonitrile Chemical compound N1=C(C)C(CC)=NC(C#N)=C1N1CCC(C=2C=CC=CC=2)CC1 ARTMWBNETUDYDF-UHFFFAOYSA-N 0.000 claims 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01113379 | 2001-06-01 | ||
| PCT/EP2002/005788 WO2002098864A1 (en) | 2001-06-01 | 2002-05-27 | Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004536814A JP2004536814A (ja) | 2004-12-09 |
| JP2004536814A5 true JP2004536814A5 (https=) | 2005-09-15 |
| JP4049742B2 JP4049742B2 (ja) | 2008-02-20 |
Family
ID=8177617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003501988A Expired - Fee Related JP4049742B2 (ja) | 2001-06-01 | 2002-05-27 | グルタミン酸受容体としてのピリミジン、トリアジン及びピラジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6673795B2 (https=) |
| EP (1) | EP1397351B1 (https=) |
| JP (1) | JP4049742B2 (https=) |
| KR (1) | KR100602927B1 (https=) |
| CN (1) | CN1245391C (https=) |
| AR (1) | AR036075A1 (https=) |
| AT (1) | ATE448210T1 (https=) |
| AU (1) | AU2002319183B2 (https=) |
| BR (1) | BR0210102A (https=) |
| CA (1) | CA2448602C (https=) |
| DE (1) | DE60234338D1 (https=) |
| DK (1) | DK1397351T3 (https=) |
| ES (1) | ES2332505T3 (https=) |
| MX (1) | MXPA03010822A (https=) |
| PT (1) | PT1397351E (https=) |
| WO (1) | WO2002098864A1 (https=) |
| ZA (1) | ZA200308859B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| UA92450C2 (ru) * | 2003-01-14 | 2010-11-10 | Арена Фармасьютикалз, Инк. | 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия |
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| EP1927594A1 (en) * | 2003-01-14 | 2008-06-04 | Arena Pharmaceuticals, Inc. | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| CA2519954A1 (en) | 2003-03-26 | 2004-10-14 | Merck & Co., Inc. | Benzamide modulators of metabotropic glutamate receptors |
| DE10320785A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
| DE10328479A1 (de) | 2003-06-25 | 2005-01-13 | Bayer Ag | 6-Arylamino-5-cyano-4-pyrimidinone |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| RS20060018A (sr) | 2003-07-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja |
| CA2531619A1 (en) * | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| SE0303492D0 (sv) * | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use VII |
| DE102004001873A1 (de) * | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
| MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| EP1827438B2 (en) | 2004-09-20 | 2014-12-10 | Xenon Pharmaceuticals Inc. | Piperazin derivatives for inhibiting human stearoyl-coa-desaturase |
| WO2007081630A2 (en) * | 2005-12-21 | 2007-07-19 | Janssen Pharmaceutica, N.V. | Substituted pyrimidinyl kinase inhibitors |
| US8278446B2 (en) * | 2005-12-21 | 2012-10-02 | Janssen Pharmaceutica N.V. | Process for preparing substituted diaminopyrimidine oximes |
| US8153791B2 (en) * | 2005-12-21 | 2012-04-10 | Janssen Pharmaceutica N.V. | Substituted pyrimidinyl oxime kinase inhibitors |
| US7834178B2 (en) * | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
| US8013153B2 (en) * | 2006-03-23 | 2011-09-06 | Janssen Pharmaceutica, N.V. | Substituted pyrimidine kinase inhibitors |
| JP5498392B2 (ja) | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用 |
| CN102046609B (zh) * | 2008-03-31 | 2014-05-14 | 全药工业株式会社 | 具有细胞保护效果的嘧啶衍生物及其应用 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| KR20110063447A (ko) | 2008-09-08 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 피라졸로피리미딘 및 ｃｎｓ 장애의 치료를 위한 이들의 용도 |
| PT2414363E (pt) | 2009-03-31 | 2014-02-26 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a |
| EP2603511B1 (en) | 2010-08-12 | 2017-03-15 | Boehringer Ingelheim International GmbH | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
| EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| CN106103421B (zh) | 2014-02-14 | 2019-04-09 | 武田药品工业株式会社 | Gpr6的吡嗪调节剂 |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| CN105255887B (zh) * | 2015-07-17 | 2018-05-18 | 四川大学 | 一种重组慢病毒及其在制备治疗可卡因成瘾的药物中的用途 |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| JP7142675B2 (ja) * | 2017-03-26 | 2022-09-27 | 武田薬品工業株式会社 | Ｇｐｒ６のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1074549B1 (en) * | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
-
2002
- 2002-05-27 DK DK02748720.6T patent/DK1397351T3/da active
- 2002-05-27 EP EP02748720A patent/EP1397351B1/en not_active Expired - Lifetime
- 2002-05-27 JP JP2003501988A patent/JP4049742B2/ja not_active Expired - Fee Related
- 2002-05-27 AU AU2002319183A patent/AU2002319183B2/en not_active Ceased
- 2002-05-27 KR KR1020037015685A patent/KR100602927B1/ko not_active Expired - Fee Related
- 2002-05-27 DE DE60234338T patent/DE60234338D1/de not_active Expired - Lifetime
- 2002-05-27 CA CA002448602A patent/CA2448602C/en not_active Expired - Fee Related
- 2002-05-27 AT AT02748720T patent/ATE448210T1/de not_active IP Right Cessation
- 2002-05-27 PT PT02748720T patent/PT1397351E/pt unknown
- 2002-05-27 ES ES02748720T patent/ES2332505T3/es not_active Expired - Lifetime
- 2002-05-27 BR BR0210102-5A patent/BR0210102A/pt not_active Application Discontinuation
- 2002-05-27 CN CNB028109872A patent/CN1245391C/zh not_active Expired - Fee Related
- 2002-05-27 WO PCT/EP2002/005788 patent/WO2002098864A1/en not_active Ceased
- 2002-05-27 MX MXPA03010822A patent/MXPA03010822A/es active IP Right Grant
- 2002-05-29 US US10/157,338 patent/US6673795B2/en not_active Expired - Fee Related
- 2002-05-31 AR ARP020102040A patent/AR036075A1/es unknown
-
2003
- 2003-11-13 ZA ZA200308859A patent/ZA200308859B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536814A5 (https=) | ||
| JP5650735B2 (ja) | タンパク質キナーゼ調節剤としてのピリジンおよびピラジン誘導体 | |
| JP2010525023A5 (https=) | ||
| HRP20160118T1 (hr) | HETEROCIKLIÄŚKI DERIVAT KAO INHIBITOR MIKROSOMSKIH SINTAZA PROSTAGLANDINA E (mPGEs) | |
| JP2020524687A5 (https=) | ||
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| JP2014531465A5 (https=) | ||
| IL161493A (en) | Pyrimidine derivatives and pharmaceutical compositions containing the same | |
| AU2002363177A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors | |
| JP2004510701A5 (https=) | ||
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| JP2009504792A5 (https=) | ||
| JP2013531055A5 (https=) | ||
| RU2015100942A (ru) | Производное пиперидинилпиразолпиридина | |
| JP2016514717A5 (https=) | ||
| JP2008536867A5 (https=) | ||
| JP2016523976A5 (https=) | ||
| JP2017536342A5 (https=) | ||
| JP2004524279A5 (https=) | ||
| JP2008513405A5 (https=) | ||
| KR20110006662A (ko) | 5-하이드록시피리미딘-4-카르복사미드 화합물 | |
| JP2020500192A5 (https=) | ||
| CA2527315A1 (en) | Imidazole derivatives as glutamate receptor antagonists | |
| RU2002118301A (ru) | Пиперидин- и пиперазин-замещенные n-гидроксиформамиды в качестве ингибиторов металлопротеиназ | |
| CA2396965A1 (en) | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |